Increased risk of acute myeloid leukaemia after treatment for breast cancer
✍ Scribed by R. Renella; H.M. Verkooijen; G. Fioretta; G. Vlastos; J. Kurtz; A.P. Sappino; P. Schäfer; I. Neyroud-Caspar; C. Bouchardy
- Book ID
- 113506763
- Publisher
- Elsevier Science
- Year
- 2006
- Tongue
- English
- Weight
- 150 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0960-9776
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. __In vitro__ clofarabine has demonstrated synergy with daunorubicin and Ara‐C and in phase II clinical trials has shown promising activ
## Abstract We report here a patient with relapsed follicular lymphoma who developed secondary acute myeloid leukaemia 15 months after radioimmunotherapy (RIT) with ^90^Y‐ibritumomab tiuxetan, the fifth described case to date. We review the literature for the potential causal relationship between R
An increased risk of breast cancer after cholecystectomy has been proposed, but the results in different studies have not been consistent. To explore this potential association, we conducted a large, population-based, record-linkage, cohort study in Sweden. The cohort consisted of 154,283 women who